- Nordihydrocapsaicin
-
- $47.00 / 1mg
-
2026-05-11
- CAS:28789-35-7
- Min. Order:
- Purity: 99.77%
- Supply Ability: 10g
- Nordihydrocapsaicin
-
- $0.00 / 5mg
-
2023-02-24
- CAS:28789-35-7
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | NORDIHYDROCAPSAICIN Basic information |
| Product Name: | NORDIHYDROCAPSAICIN | | Synonyms: | Octanamide,N-[(4-hydroxy-3-methoxyphenyl)methyl]-7-methyl-;NORDIHYDROCAPSAICIN;N-[(4-Hydroxy-3-methoxyphenyl)methyl]-7-methyl-octanamide;Norhydrocapsaicin;N-(4-Hydroxy-3-methoxybenzyl)-7-methyloctanamide;Nordihydrocapsaic;NORDIHYDROCAPSAICIN USP/EP/BP;Nordihydrocapsaicin-RM | | CAS: | 28789-35-7 | | MF: | C17H27NO3 | | MW: | 293.4 | | EINECS: | | | Product Categories: | Miscellaneous Natural Products | | Mol File: | 28789-35-7.mol |  |
| | NORDIHYDROCAPSAICIN Chemical Properties |
| Boiling point | 487.0±35.0 °C(Predicted) | | density | 1.036±0.06 g/cm3 (20 ºC 760 Torr) | | storage temp. | 2-8°C | | solubility | Chloroform: soluble; DMSO: soluble | | pka | 9.76±0.20(Predicted) | | form | A crystalline solid | | color | Light brown to gray | | InChI | InChI=1S/C17H27NO3/c1-13(2)7-5-4-6-8-17(20)18-12-14-9-10-15(19)16(11-14)21-3/h9-11,13,19H,4-8,12H2,1-3H3,(H,18,20) | | InChIKey | VQEONGKQWIFHMN-UHFFFAOYSA-N | | SMILES | C(NCC1=CC=C(O)C(OC)=C1)(=O)CCCCCC(C)C | | LogP | 3.046 (est) | | EPA Substance Registry System | Nordihydrocapsaicin (28789-35-7) |
| | NORDIHYDROCAPSAICIN Usage And Synthesis |
| Uses | Nordihydrocapsaicin is a capsaicinoid and analog and congener of capsaicin in chili peppers. | | Definition | ChEBI: Nordihydrocapsaicin is a member of methoxybenzenes and a member of phenols. | | in vivo | Nordihydrocapsaicin (0.1-0.2% CAPs (10 mg/kg BW), p.o., daily for 8 weeks) prevents low-fat-high carbohydrate diet and high-fat diet-induced obesity by regulating the NADPH oxidase and Nrf2 pathways in rats[4].
| Animal Model: | Wistar rats [4] | | Dosage: | 0.1%–0.2% CAPs (10 mg/kg BW) | | Administration: | p.o., daily for 8 weeks | | Result: | Caused a 32% and 37% reduction for HSD and 16% and 18% reduction for HFD in serum and liver MDA concentrations and elevation in serum TAC by 163% and 54% in the HSD- and HFD-fed rats (P<0.001), respectively. |
|
| | NORDIHYDROCAPSAICIN Preparation Products And Raw materials |
|